BioSpace News Archive

The global contact lens market is projected to witness considerable rise owing to rising prevalence of increased preference for contact lenses over prescribed eyeglasses for aesthetics purposes and rising cases of vision related problems like myopia.

Oncopeptides AB, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the first quarter 2021 on May 26.

Funded by the Bill & Melinda Gates Foundation and Global Grand Challenges Canada’s Saving Lives at Birth initiative, the two research and validation studies include the integration of Biospectal OptiBP and focus on the routine measurement of blood pressure as well as assessment of hypertension during pregnancy [20-May-2021] SAN FRANCISCO and LAUSANNE, Switzerland

Elekta invites investors, analysts and financial media representatives to join Elekta’s digital Capital Markets Day on June 7, 2021.

Pfizer Inc. and BioNTech SE announced that the BioNTech Europe GmbH has entered into an agreement with Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ COVID-19 vaccine, with an option for an additional 30 million doses.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, reported financial results for the quarter ended March 31, 2021 and provided an update on its clinical programs.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. to approximately 12:30 p.m. ET, May 20, 2021.

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced they have entered into an exclusive collaboration agreement with the National Cancer Center Japan to provide Caris’ comprehensive molecular profiling in MONSTAR-SCREEN-2 of SCRUM-Japan, the largest cancer genomic screening consortium in Japan.

Data demonstrated that XTX202, an engineered, tumor-selective IL-2, increased tumor growth inhibition without dose-limiting toxicities in preclinical studies

Merck, known as MSD outside the United States and Canada, announced V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 Phase 3 pediatric clinical program.